VVOS - Vivos Therapeutics CARE Oral Medical Devices Qualify for Full Medicare Reimbursement

2024-04-09 08:43:00 ET

DENVER, Colo., Apr 09, 2024 ( 247marketnews.com )- Vivos Therapeutics, Inc. (NASDAQ: VVOS ) reported that its CARE Oral Medical Devices is the first oral appliance for the treatment of all severities of obstructive sleep apnea in adults to receive all required regulatory approvals to enable Medicare reimbursement, effective immediately, allowing millions of Medicare beneficiaries coverage and reimbursement for allowable charges billable to Medicare.

“Prior to these latest developments, moderate to severe OSA patients on Medicare were relegated almost entirely to a lifetime of some form of CPAP—something most patients find undesirable. Our CARE oral medical devices, on the other hand, can significantly improve and even resolve OSA in about 12 months, with no further intervention required in most cases,” stated Kirk Huntsman, Vivos Chairman and Chief Executive Officer. “We are very pleased the Centers for Medicare and Medicaid Services (CMS) recognizes and validates the benefits our FDA cleared devices can have on the lives of patients diagnosed with OSA. Now these novel and patented devices, which have been proven effective for all levels of OSA severity in adults from mild to severe, can be accessible to more people with less out of pocket cost. We believe this latest regulatory approval represents an inflection point for our devices and will open the door for more OSA patients who have Medicare or commercial medical insurance coverage to receive treatment from Vivos-trained professionals utilizing our proprietary core technology and treatment protocols. This should also drive increased patient count and utilization of our Vivos Devices and Method.”

The post Vivos Therapeutics CARE Oral Medical Devices Qualify for Full Medicare Reimbursement appeared first on 24/7 MarketNews .

For further details see: